Researchers identify bone-forming cells as the driver of scoliosis caused by a genetic disorder, which can be prevented ...

Pasithea Therapeutics Corp. has announced the successful enrollment and initial dosing of three subjects in Cohort 6 of its Phase 1 clinical trial for PAS-004, a candidate for treating ...

Spinal deformities such as scoliosis and kyphosis are among the most serious complications of neurofibromatosis type 1 (NF1), a genetic disorder that affects about one in 3,000 people. These ...

When the NF1 gene was discovered in 1990, it was quickly learned that the gene product functions as a regulator of a protein called Ras. Ras is a key component of a cell signaling pathway that ...

The Global Plexiform Neurofibroma Market centers on the treatment of plexiform neurofibromas, benign nerve sheath tumors linked to Neurofibromatosis Type 1 (NF1). These tumors cause significant ...

The US Food and Drug Administration has approved mirdametinib for the treatment of neurofibromatosis type 1 (NF1) in adults and children. The drug, developed by SpringWorks Therapeutics, is the first ...

A new study led by Indiana University School of Medicine researchers revealed a potential strategy to address neurobehavioral challenges associated with neurofibromatosis type 1, or NF1, a genetic ...

Almost half of adults and children with neurofibromatosis type 1 (NF1) responded to the investigational MEK inhibitor mirdametinib, a large multicenter study of the rare condition showed. Overall, 53 ...

Neurofibromatosis type 1 (NF1) is a genetic condition that causes tumors to grow along nerves in the skin, brain, and other parts of the body. These tumors are usually noncancerous (benign), but they ...